Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060255 · ClinicalTrials.gov registry record · Phase 2
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 451
- Enrollment target
NCT00060255 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 451 participants.
The verdict
NCT00060255, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 451 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation or autologous bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well eight different high-dose chemotherapy regimens with or without total-body irradiation followed by autologous stem cell transplantation or autologous bone marrow transplantation works in treating patients with hematologic malignancies or solid tumors.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG carmustine
- DRUG busulfan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 1991-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060255
The ClinicalTrials.gov registry entry for NCT00060255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 451 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00060255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060255 about?
NCT00060255 is a clinical study titled "High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors". RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation or autologous bone marrow transplantation may al...
What is the current status of trial NCT00060255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 451 participants. The study started on 1991-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00060255?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), carmustine (DRUG), busulfan (DRUG).
Who is sponsoring clinical trial NCT00060255?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.